Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Profit After Tax (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Profit After Tax data on record, last reported at -$5.3 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 17.81% year-over-year to -$5.3 million; the TTM value through Sep 2025 reached -$19.4 million, up 9.24%, while the annual FY2024 figure was -$20.4 million, 8.34% up from the prior year.
  • Profit After Tax reached -$5.3 million in Q3 2025 per GANX's latest filing, up from -$5.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$2.5 million in Q1 2021 and bottomed at -$8.1 million in Q2 2024.
  • Average Profit After Tax over 5 years is -$4.7 million, with a median of -$4.7 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: tumbled 554.57% in 2021, then grew 28.66% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$3.2 million in 2021, then crashed by 45.17% to -$4.7 million in 2022, then decreased by 1.06% to -$4.7 million in 2023, then rose by 20.23% to -$3.8 million in 2024, then plummeted by 40.23% to -$5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$5.3 million in Q3 2025, -$5.8 million in Q2 2025, and -$4.5 million in Q1 2025.